Logo Image
Opinion|Videos|February 3, 2025

Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.

Episodes in this series

Video content above is prompted by the following:

  • 2023 AAAAI/ACAAI Joint Task Force Practice Parameters and Guidelines (Ann Allergy Asthma Immunol 2024;132:274-312).
  • Discuss the treatment options with strong recommendations and high certainty of evidence.
  • Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
  • JAK inhibitors: abrocitinib, baricitinib, upadacitinib

Related Content

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update
Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

View more